Ivfarma received from the Ministry of Health of the Russian Federation a registration certificate for the drug “Cetrorelix” (cetrorelix) – a generic version of the reference “Cetrotide” which is Merck’s product . The drug is applicable in the field of assisted reproductive technologies (ART).
The drug causes a delay in the rise in luteinizing hormone levels in women, which delays the onset of ovulation. This is necessary to prevent premature ovulation in patients of ART clinics with controlled stimulation of ovulation.